Effect of the neridronate on RANKL release in differentiated primary human osteoblasts
Drugs and Therapy Studies · 2011
DOI: 10.4081/dts.2011.e3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drugs and Therapy Studies, 2011. Verfasst von Vanessa Nicolin und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Bisphosphonates are important inhibitors of bone resorp- tion and widely used clinically to treat osteoporosis, metabolic bone diseases and other orthopaedic disorders . Inhibiting osteoclasts via the mevalonate pathway is recognized as the primary mechanism of its inhibitory action. Recent evidence suggests that bisphosphonates may regulate essential signaling molecules involved in osteoclastogenesis such as RANKL (receptor activator of NF-kB ligand) which are synthesized by osteoblasts. In this report we have investigated into the neridronate-osteoblast interactions in modulating essential signaling molecule such as RANKL.
Zitieren
APA
Nicolin, V., Valentini, R., Bortul, R., & Fancellu, G. (2011). Effect of the neridronate on RANKL release in differentiated primary human osteoblasts. Drugs and Therapy Studies. https://doi.org/10.4081/dts.2011.e3
Vancouver
Nicolin V, Valentini R, Bortul R, Fancellu G. Effect of the neridronate on RANKL release in differentiated primary human osteoblasts. Drugs and Therapy Studies. 2011. doi:10.4081/dts.2011.e3
BibTeX
@article{Nicolin2011,
author = {Nicolin, Vanessa and Valentini, Roberto and Bortul, Roberta and Fancellu, Giovanni},
title = {Effect of the neridronate on RANKL release in differentiated primary human osteoblasts},
journal = {Drugs and Therapy Studies},
year = {2011},
doi = {10.4081/dts.2011.e3}
}
EUVIMED